As our knowledge of liver physiology expands, so too does our understanding of the critical role played by the vascular system in both the development and progression of liver disease. While liver sinusoidal changes are known to affect disease progression, they also have a knock-on effect, disrupting circulation in the rest of the body. The Cirrhosis and Complications track at Digital ILC 2020 will explore the complex relationship between vascular changes and liver cirrhosis, and will highlight the management of portal hypertension.
In its quest to beat liver disease, EASL efforts include devoting a full track to this topic at its events, supporting consortia and collaborations aimed at advancing pertinent research, and having published the EASL Clinical Practice Guidelines on the Management of Decompensated Cirrhosis, which are consulted worldwide.
The Cirrhosis and Complications programme will allow you to learn, share, and interact, due to its engaging structure containing poster tours, abstract sessions, interactive sessions, industry symposia, meet the experts, and wrap up sessions.
Digital ILC 2020 highlights: portal hypertension
What progress is underway in the field of portal hypertension? What are its key developments from research and trials?
To find out how this research field has evolved since ILC 2019, watch this video, “Portal hypertension highlights” from the session Co-chair, Dr Virginia Hernandez-Gea.
Explore the Cirrhosis and Complications track at Digital ILC 2020
Abstract session: Cirrhosis – Experimental aspects
27 August 2020 15:30 – 17:00
Chairs: Shilpa Chokshi (United Kingdom) & Wim Laleman (Belgium)
Abstract session: Portal Hypertension
28 August 2020 11:00 – 12:30
Chairs: Alexander Gerbes (Germany) & Virginia Hernandez-Gea (Spain)
Abstract session: Complications of cirrhosis and ACLF
29 August 2020 11:00 – 12:30
Chairs: Elsa Solà (Spain) & Mauro Bernardi (Italy)
Poster tour: Cirrhosis: ACLF and critical illness
27 August 2020 15:00 – 15:30
Chair: Thierry Gustot (Belgium)
Poster tour: Cirrhosis and its complications: Clinical
28 August 2020 12:30 – 13:00
Chair: Juan Carlos Garcia Pagan (Spain)
Poster tour: Cirrhosis and its complications: Experimental and pathophysiology
28 August 2020 15:00 – 15:30
Chair: Christian Trautwein, Germany
Get prepared for Digital ILC 2020
Educational resources from EASL Campus
Selected articles from the Journal of Hepatology
- Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation
- FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis
- Development of chronic kidney disease after acute kidney injury in patients with cirrhosis is common and impairs clinical outcomes
- Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF
EASL Clinical Practice Guideline – Management of Decompensated Cirrhosis
When the panel of experts nominated by EASL began work to update the Clinical Practice Guidelines on ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS), it became obvious that they should cover all other complications of decompensated cirrhosis.
Within this framework, a formal definition of decompensated cirrhosis was sought. A silent, asymptomatic course characterizes the natural history of cirrhosis. This until increasing portal pressure and worsening liver function produce a clinical phenotype. In the asymptomatic phase of the disease, usually referred to as compensated cirrhosis, patients may have a good quality of life. Also, the disease may progress undetected for several years. The development of overt clinical signs marks the decompensation. The most frequent of which are ascites, bleeding, encephalopathy, and jaundice.